Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FHCT003
- Development stage
- Unknown
- Lead developer
- FullHope Biomedical
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
FHCT003 is an autologous immune cell therapy developed by FullHope Biomedical, a Taiwan-based biotechnology company. The therapy is engineered to target the vascular endothelial growth factor (VEGF) pathway, thereby inhibiting tumor angiogenesis—the process by which tumors develop their own blood supply. By disrupting this pathway, FHCT003 aims to starve tumors of nutrients and oxygen, inhibiting their growth and progression. It is currently under investigation in Phase 1/2 clinical trials for the treatment of various cancers and tumor angiogenesis-related conditions, utilizing FullHope's precision immunoprofiling platform for personalized treatment.
Beyond the preview
Go deeper on FHCT003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FHCT003.